Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

Objectives To investigate the potential association between tumour necrosis factor (TNF) inhibitor treatment and malignant melanomas in rheumatoid arthritis, melanoma risks in rheumatoid arthritis patients not treated with biological drugs, and risk of all site cancer with TNF inhibitors as used in rheumatoid arthritis. Design Population based cohort study. Setting Prospectively recorded data from national clinical, health, and demographic registers in Sweden 2001-10. Patients with rheumatoid arthritis treated (n=10 878) or not (n=42 198) with TNF inhibitors and matched general population comparators (n=162 743). Main outcome measures The primary outcome was first invasive melanoma in people without any history of invasive cancer of any type. Hazard ratios were estimated using Cox regression, comparing non-biological drug treated rheumatoid arthritis patients with the general population comparator and TNF inhibitor treated rheumatoid arthritis patients with those not treated with biological drugs. Secondary outcomes included in situ melanomas, second primary melanomas, and all site cancer. Results 113 first invasive melanomas occurred in rheumatoid arthritis patients not treated with biological drugs, and 393 occurred in the general population comparator cohort. Rheumatoid arthritis patients not treated with biological drugs were not at significantly increased risk of melanoma compared with the general population (hazard ratio 1.2, 95% confidence interval 0.9 to 1.5). 38 first invasive melanomas occurred in rheumatoid arthritis patients treated with TNF inhibitors; these patients had an increased risk of melanoma compared with rheumatoid arthritis patients not treated with biological drugs (hazard ratio 1.5, 1.0 to 2.2; 20 additional cases per 100 000 person years). The risk of a second primary melanoma was non-significantly increased (hazard ratio 3.2, 0.8 to 13.1; n=3 v 10) in rheumatoid arthritis patients treated with TNF inhibitors compared with those not treated with biological drugs. Conclusion Overall, patients with rheumatoid arthritis who have not been treated with biological drugs are not at increased risk of invasive melanoma compared with the general population. Rheumatoid arthritis patients selected for TNF inhibitor treatment are not at increased overall risk for cancer but have a 50% increased relative risk of invasive melanoma. Given the small increase in absolute risk, these finding may not markedly shift the overall risk-benefit balance of TNF inhibitors as used in clinical practice but might do so in patients at high risk of melanoma for other reasons.

[1]  A. Loft,et al.  Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO Registry , 2012, Annals of the rheumatic diseases.

[2]  D. Solomon,et al.  Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. , 2013, Arthritis and rheumatism.

[3]  M. Suarez‐Almazor,et al.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.

[4]  E. Rahme,et al.  Melanoma and rheumatoid arthritis (brief report) , 2012, Clinical Rheumatology.

[5]  Hana Jeon,et al.  Letter: Methotrexate for localized morphea with severe pain: a case report. , 2011, Dermatology Online Journal.

[6]  P. Calzavara-Pinton,et al.  Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report. , 2011, Dermatology Online Journal.

[7]  T. Torres,et al.  Letter: Penile Kaposi sarcoma: A case of complete resolution with highly active antiretroviral therapy alone. , 2011, Dermatology Online Journal.

[8]  A. Eggermont,et al.  Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha , 2011, Current opinion in oncology.

[9]  D. Symmons,et al.  Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data , 2011, Pharmacoepidemiology and drug safety.

[10]  M. Neovius,et al.  Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden , 2010, Annals of the rheumatic diseases.

[11]  M. Neovius,et al.  Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register , 2010, Annals of the rheumatic diseases.

[12]  U. Trefzer,et al.  Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma , 2011, Journal of Cancer Research and Clinical Oncology.

[13]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[14]  J. Neuberger,et al.  Comparison of the Incidence of Malignancy in Recipients of Different Types of Organ: A UK Registry Audit , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  W. Dixon,et al.  SPECIAL ARTICLE: DRUG SAFETY IN THE RHEUMATIC DISEASES Influence of Anti–Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology , 2022 .

[16]  N. Stavrianeas,et al.  Development of Two Primary Malignant Melanomas after Treatment with Adalimumab: A Case Report and Review of the Possible Link between Biological Therapy with TNF-α Antagonists and Melanocytic Proliferation , 2010, Dermatology.

[17]  Victor R. Preedy,et al.  International Classification of Disease , 2010 .

[18]  L. Jacobsson,et al.  Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? , 2009, Arthritis and rheumatism.

[19]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[20]  E. Matteson,et al.  Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials , 2008, Annals of the rheumatic diseases.

[21]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[22]  A. Eggermont,et al.  Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[23]  M. Mihm,et al.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. , 2009, Cancer immunity.

[24]  G. Giles,et al.  Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. , 2008, Arthritis and rheumatism.

[25]  M. Herlyn,et al.  Melanoma stem cells: the dark seed of melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Farmer,et al.  Risk of skin cancer in the drug treatment of rheumatoid arthritis. , 2008, Expert opinion on drug safety.

[27]  F. Wolfe,et al.  Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. , 2007, Arthritis and rheumatism.

[28]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[29]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[30]  J. Drabick,et al.  Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. , 2007, Journal of the American Academy of Dermatology.

[31]  J. Kaldor,et al.  Cancer incidence before and after kidney transplantation. , 2006, JAMA.

[32]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[33]  K. Alam,et al.  The treatment of melanoma with an emphasis on immunotherapeutic strategies. , 2006, Surgical oncology.

[34]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[35]  P. Hwu,et al.  Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention , 2006, Clinical Cancer Research.

[36]  A. Iliadou,et al.  Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[37]  H. Comber,et al.  A population‐based study of skin cancer incidence and prevalence in renal transplant recipients , 2006, The British journal of dermatology.

[38]  L. Klareskog,et al.  Swedish registers to examine drug safety and clinical issues in RA , 2006, Annals of the rheumatic diseases.

[39]  J. Avorn,et al.  Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[40]  B. Kasiske,et al.  Cancer after Kidney Transplantation in the United States , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[41]  P. Carli,et al.  Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. , 2003, Journal of the American Academy of Dermatology.

[42]  G. Macfarlane,et al.  Risk of malignancy among patients with rheumatic conditions , 2000, International journal of cancer.

[43]  S. Tóth,et al.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.

[44]  J. Olsen,et al.  Rheumatoid arthritis and cancer risk. , 1996, European journal of cancer.

[45]  N. Chakraborty,et al.  Immunobiology and immunotherapy of melanoma , 1995, Current opinion in oncology.

[46]  J. F. Fraumeni,et al.  Incidence of cancer among patients with rheumatoid arthritis. , 1993, Journal of the National Cancer Institute.